大型安全网医院接受放射治疗的被监禁个体诊断时癌症分期的不平等
该研究回顾性分析了2003年1月至2019年5月在一家大型安全网医院接受放射治疗的80名被监禁患者的人口学和临床病理特征。结果显示多数患者诊断时即为III期和IV期癌症,且随访率低,即使在早期疾病患者中也是如此。作者认为需要努力理解和减轻被监禁患者中持续存在的健康不平等。
要点
- 80名被监禁患者中,46.3%(n=38)诊断时为IV期癌症,17.1%(n=14)为III期。
- 80.5%的患者接受了放射治疗,6个月、1年和5年随访率分别为41.5%、27.7%和3.1%。
- 早期(I-III期)患者随访率同样偏低,6个月、1年和5年分别为41.9%、22.6%和3.2%。
核心结论
- 该研究突显了被监禁这一脆弱患者群体在癌症诊断分期上的不平等,该群体在很大程度上被排除在临床研究之外。
- 多数被监禁患者诊断时即为III期和IV期癌症,且即使早期疾病患者随访率也低。
- 作者认为需要努力理解和减轻被监禁患者中持续存在的健康不平等。
研究设计与样本
- 回顾性综述,经IRB批准,识别了2003年1月至2019年5月期间接受放射治疗的80名被监禁患者。
- 分析了患者、肿瘤类型和分期、治疗因素及随访率的描述性统计。
主要发现
- 80名个体共有82个癌症诊断,中位年龄54岁(范围46-64岁)。
- 白人、黑人和「其他」种族分别占61.3%(n=49)、28.8%(n=23)和10%(n=8)。
- 男性占93.8%(n=75),英语使用者占95%(n=76);50%(n=40)有物质使用障碍史,75%(n=60)有吸烟史。
- 最常见的癌症类型为头颈部(n=21,25.6%)、胸部(n=17,20.7%)、胃肠道(n=14,17.1%)和前列腺(n=12,14.6%)。
- AJCC分期分布为I期(n=12,14.6%)、II期(n=12,14.6%)、III期(n=14,17.1%)、IV期(n=38,46.3%)和未知/不可用(n=6,7.3%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: There is a dearth of data on cancer care in the incarcerated population, despite being the leading cause of illness-related death in United states' prisons. We retrospectively reviewed the demographic and clinicopathologic characteristics of incarcerated individuals who received radiation therapy at a large safety-net hospital. METHODS: Following IRB approval, we identified 80 incarcerated patients who presented for radiation therapy between January 2003 and May 2019. Descriptive statistics on the patients, tumor types and stage, treatment factors, and follow-up rates were analyzed. RESULTS: 80 individuals with 82 cancer diagnoses presented for radiation oncology consultation over the study period. The median age was 54 years (range, 46-64). Patients of White, Black, and "other" races comprised 61.3% (n=49), 28.8% (n=23), and 10% (n=8), respectively. Most patients were male (n=75, 93.8%) and English speakers (n=76, 95%). Moreover, 50% (n=40) had a substance use disorder history and 75% (n=60) had a smoking history. The three most common cancer types were prostate (n=12, 14.6%), gastrointestinal (n=14, 17.1%), thoracic (n=17, 20.7%), and head and neck (n=21, 25.6%). The distribution of tumor stage (AJCC) was I (n=12, 14.6%), II (n=12, 14.6%), III (n=14, 17.1%), IV (n=38, 46.3%), and unknown/unavailable (n=6, 7.3%). Of the cohort, 65 patients with 66 cancers (80.5%) received radiation. Among them, the 6-month, 1-year, and 5-year follow-up rates were 41.5%, 27.7%, and 3.1%, respectively. Subset analysis limited to stage I-III patients (n=30) revealed 6-month, 1-year and 5-year follow-up rates of 41.9%, 22.6%, and 3.2%, respectively. CONCLUSIONS: This study highlights inequalities in cancer stage at diagnosis among a vulnerable patient population that is largely excluded from clinical research. Majority of the incarcerated patients presented with stage III & IV cancers and have poor follow up rates even among those with early-stage disease. Efforts to understand and mitigate persistent health inequalities among incarcerated patients are warranted.
引用
- Oladeru OT, Lam CM, Qureshi MM, et al. Inequalities in Cancer Stage at Diagnosis Among Incarcerated Individuals Undergoing Radiation Therapy at a Large Safety-Net Hospital. Int J Radiat Oncol Biol Phys. 2023. PMID: 36758643. doi:10.1016/j.ijrobp.2023.02.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。